October 19, 2023
Xlife Sciences invests in 4D Lifetec
Xlife Sciences AG has invested CHF 23.3 million in 4D Lifetec AG , acquiring a 20% stake in the company.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 19, 2023
Abivax issues shares between €10.98 and €12.30 per ordinary share
Abivax kicked off book-building and the filing of an amended registration statement on Form F-1, to issue approximately 20,325,500 ordinary shares
October 19, 2023
Basilea buys privately owned Gravitas Therapeutics for clinical-stage antifungal compound
Basilea Pharmaceutica has entered into an asset purchase agreement with privately owned Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.
October 18, 2023
Ongoing investments in the supply chain for complex injectable medications
Vetter Pharma has announced additional investments of €230 million in its new production building, which is currently under construction at the company’s global corporate headquarters site in Ravensburg, as it has recently reached a significant milestone in the construction process, as the shell of the building is now complete, following the start of construction in November 2021.
October 18, 2023
Inaugural Biotech Summit Austria sets the agenda for emerging biotech innovation
The first BIOTECH SUMMIT AUSTRIA – a milestone event for the Austrian and international biotechnology community – concluded on Friday in Graz, after two days of insightful discussions and networking.
October 16, 2023
BioNTech evaluates impact of Pfizer’s wirte-offs on financial results
BioNTech is evaluating the potential impact of Pfizer’s write-offs and other charges related to COMIRNATY on its financial results.
October 13, 2023
Sanofi: amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis
Positive results from a Phase 2b study (STREAM-AD) showed that amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis in adults whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.
October 13, 2023
CHMP recognizes urgent medical need for treating Duchenne patients
CHMP has adopted a positive opinion in favor of approval of a Swiss specialty pharmaceutical company Santhera Pharmaceuticals’ AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy patients aged 4 years and older.
October 6, 2023
Medexprim appoints Chief Product and Technical Officer
Medexprim has appointed Montaine Marteau as Chief Product and Technical Officer (CPTO), concurrently with her integration into the company’s Executive Committee, alongside Romain Cazavan, Nicolas Dubost and Fabrice Pillon.
October 5, 2023
NICE recommends Jardiance for use as an option for chronic heart failure
The National Institute for Health and Care Excellence (NICE) announced Thursday that empagliflozin (Jardiance) is recommended for use as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.